
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics Inc is poised for significant growth, with annual sales for Korlym expected to increase by 19% to 26% year-over-year, driven by robust underlying demand despite recent commercial challenges. The anticipation of market expansion, especially in the Cushing's syndrome market and the promising sales trajectory for relacorilant, suggests potential peak sales of approximately $1.9 billion by 2031. Furthermore, the company’s proactive strategy to launch relacorilant with a dedicated sales force indicates confidence in capturing market share, further enhancing its growth prospects.
Bears say
Corcept Therapeutics's outlook has been negatively influenced by the issuance of a Complete Response Letter (CRL) regarding the delayed launch of relacorilant for the treatment of Cushing's Syndrome, resulting in a substantial decrease in share prices from previous highs. The downward revision of the 12-month price target from $145 to $90 per diluted share reflects the significant investor concerns surrounding future revenue projections, particularly with anticipated delays in product launches. Moreover, the company's reliance on relacorilant and its associated safety profile, coupled with market apprehensions regarding the launch of new therapies, underscores the risks that may weigh heavily on Corcept's financial performance moving forward.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares